BEAVERTON, OR, UNITED STATES, January 13, 2026 /EINPresswire.com/ -- Sedia Biosciences Corporation, a leading developer ...
In a recent study published in the journal PLOS Biology, researchers in France investigated the cellular function and antiviral role of human SAMD9L and its paralog SAMD9 (short for sterile alpha ...
The experimental HIV vaccine regimen exhibited an acceptable safety profile and elicited robust immune responses in 99% of trial participants from sub-Saharan Africa. Its ability to induce broad ...
In a recent landmark study, scientists have unveiled how HIV-1 penetrates the cell's nuclear barrier—a discovery that could reshape antiviral strategies. The research, led by Professor Peijun Zhang, ...
Scientists have unveiled insights into how HIV-1, the virus responsible for AIDS, skillfully hijacks cellular machinery for its own survival. By dissecting the molecular interplay between the virus ...
Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...
A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability that could lead to new therapies and bring the world closer to a ...
Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results